Emmaus Life Sciences, Inc. in brief
Emmaus Life Sciences, Inc. is a listed company in the Biotechnology industry, based in Torrance, California, USA. Its last known market value was $12 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $12 M and a net loss of $7 M. It employs about 33 people. Its largest product and service lines by sales in 2025 were Endari - US (73%) and Endari - International (26%).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Emmaus Life Sciences, Inc.
We are a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases. Our only product, Endari® (prescription grade L-glutamine oral powder) is approved by the U.S. Food and Drug Administration, or FDA, to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Endari® was approved for marketing in the United Arab Emirates, or U.A.E, Qatar, Kuwait, Bahrain and Oman. Our application for marketing authorization in the Kingdom of Saudi Arabia, or KSA, is pending. While the application is pending, the FDA approval of Endari® can be referenced to allow access to Endari® in Saudi Arabia on a named-patient basis. In January 2025, Endari® was afforded market exclusivity in the KSA by the KSA’s unified purchasing system which extends to all KSA government institutions, including hospitals under the Ministry of Health, Military Hospitals, the National Guard, the Security Forces, and King Faisal Specialty Hospitals and Research Centers.
From the company's annual report filed with the US SEC: read the report
Emmaus Life Sciences, Inc. timeline
- 1999
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2004
- ✎Renamed SalesTactix, Inc.Formerly Age Research Inc.
- 2005
- ✎Renamed Strativation, Inc.Formerly SalesTactix, Inc..
- 2007
- ✎Renamed Cns Response, Inc.Formerly Strativation, Inc..
- 2015
- ✎Renamed MYnd Analytics, Inc.Formerly Cns Response, Inc..
- 2019
- ✎Renamed Emmaus Life Sciences, Inc.Formerly MYnd Analytics, Inc..
- 2023
- 💰Record revenue of $30 millionFY2023, the highest of the 8 years on record.
Events of Emmaus Life Sciences, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,717 (Jan 2020) · #3,973 (Jan 2021) · #4,647 (Jan 2022) · #5,354 (Dec 2022) · #5,363 (Jul 2023)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -38.8%
- Operating margin
- 1.8%
- Return on equity
- —
- Liabilities / assets
- 396.6%
- Net debt
- $25M
- Revenue growth
- -25.2%
- R&D / revenue
- 2.5%
- Revenue per employee
- $377 K
- Profit per employee
- $-227 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $12M | -25.2% | $0M | $-7M | -60.2% |
| Dec 2024 | $17M | -43.8% | $-2M | $-6M | -38.7% |
| Dec 2023 | $30M | +61.0% | $4M | $-4M | -12.6% |
| Dec 2022 | $18M | -10.8% | $-7M | $-11M | -57.7% |
| Dec 2021 | $21M | -11.0% | $-6M | $-16M | -77.4% |
| Dec 2020 | $23M | +1.8% | $-0M | $1M | 5.8% |
| Dec 2019 | $23M | +38.2% | $-5M | $-55M | -241.1% |
| Dec 2018 | $16M | — | $-8M | $-73M | -441.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-0M | $0M | $-0M | $-0.12 | — |
| Dec 2024 | $-2M | $0M | $-2M | $-0.10 | — |
| Dec 2023 | $-2M | $0M | $-2M | $-0.07 | — |
| Dec 2022 | $-5M | $0M | $-5M | $-0.21 | — |
| Dec 2021 | $-1M | $0M | $-1M | $-0.32 | — |
| Dec 2020 | $-2M | $0M | $-2M | $30.00 | — |
| Dec 2019 | $-5M | $0M | $-5M | $-1.30 | — |
| Dec 2018 | $-6M | $0M | $-6M | $-1.97 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $6M (+124.1% on a year earlier), net income $1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Aug 14, 20268-KCurrent reportResults of operations
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- May 15, 20268-KCurrent reportResults of operations
- May 15, 202610-QQuarterly report · period to Mar 2026
- Apr 17, 20268-KCurrent reportDirectors or officers changed
- Apr 14, 20268-KCurrent reportDirectors or officers changed
- Mar 31, 20268-KCurrent reportResults of operations
- Mar 31, 202610-KAnnual report · period to Dec 2025
- Mar 4, 20268-KCurrent reportMaterial agreement
- Dec 31, 20258-KCurrent reportMaterial agreement · Other events
- Dec 22, 20258-KCurrent reportMaterial agreement · New financial obligation · Unregistered share sale
- Dec 19, 20258-KCurrent reportDirectors or officers changed
Official filings of Emmaus Life Sciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $12 M
- Operating income
- $0 M
- Net income
- $-7 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $21 M
- Total liabilities
- $85 M
- Total equity
- $-64 M
As of December-2025
Insider trading at Emmaus Life Sciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Willis C. LeeCEO, Director | Buyindirect | +100,000 | $0.050 | $5 K | 690,167 | Form 4 |
| filed | Willis C. LeeCEO, Director | Buyindirect | +94,767 | $0.060 | $6 K | 590,167 | Form 4 |
| filed | Willis C. LeeCEO, Director | Buyindirect | +50,000 | $0.050 | $3 K | 495,400 | Form 4 |
| filed | Willis C. LeeCEO, Director | Buyindirect | +46,000 | $0.040 | $2 K | 445,400 | Form 4 |
| filed | Willis C. LeeCEO, Director | Buyindirect | +170,000 | $0.010 | $2 K | 275,400 | Form 4 |
| filed | Willis C. LeeCEO, Director | Buyindirect | +70,000 | $0.020 | $1 K | 229,400 | Form 4 |
| filed | Seah H. LimDirector | Buy | +20,000 | $0.040 | $800 | 4.61 M | Form 4 |
| filed | Willis C. LeeCo-President & COO, Director | Buyindirect | +77,000 | $0.130 | $10 K | 159,400 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Emmaus Life Sciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Emmaus Life Sciences, Inc. scorecard#
Passes 3 of the 15 checks that could be worked out: strongest in profitability (2 of 4), weakest in growth (0 of 6). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 6
- ✗Revenue grew in the newest year-25.2%Revenue down 25.2% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-12.2%-12.2% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-12.2%-12.2% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.12 vs -0.10Diluted EPS -0.12 in fiscal 2025 against -0.10 the year before (report's currency).
- ✗Net income higher than five years earlier-$7 M-$7 M in fiscal 2025 against $1 M in 2020.
- ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
Profitability2 of 4
- ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median1.9%1.9% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier1.9%1.9% in fiscal 2025 against -35.8% in 2022.
Financial health0 of 4
- ✗Short-term assets cover short-term liabilities0.1×Current ratio 0.11 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- ✗Net debt below three years of EBITDA92.6×Net debt 92.6 times EBITDA in fiscal 2025.
- ✗Operating income covers interest five times0.0×Operating income 0.0 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.3%Diluted shares up 1.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Emmaus Life Sciences, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 1.9% | -60.5% | |
| Net margin | -60.2% | -68.9% | |
| Revenue growth, 3 years a year | -12.2% | 12.9% | |
| Revenue growth | -25.2% | 15.8% | |
| Free cash flow margin | -0.1% | -61.5% |
3of 9on the Piotroski tests of financial strength
- Revenue fell 25.2% against the year before.
- Net loss of $7 million, the 5th loss-making year in a row.
- Free cash flow was negative: -$0 million.
- Shareholders' equity is negative: -$64 million.
Emmaus Life Sciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Sep 30, 2018 | FY 2017to Sep 30, 2017 | FY 2016to Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 12−25.2%100% | 17−43.7%100% | 30+60.9%100% | 18−10.8%100% | 21−11.0%100% | 23+1.8%100% | 23+1630%100% | 1.3+924%100% | 0.1+51.0%100% | 0.1—100% | |
| Cost of revenue | 0.9−28.6%6.9% | 1.2−10.5%7.2% | 1.3−48.1%4.5% | 2.6−21.9%14.1% | 3.3+47.3%16.1% | 2.2+105%9.7% | 1.1+32.2%4.8% | 0.8+1447%62.9% | 0.1+873%41.6% | 0.0—6.5% | |
| Gross profit | 12−25.0%93.1% | 15−45.3%92.8% | 28+78.8%95.5% | 16−8.6%85.9% | 17−17.3%83.9% | 21−3.4%90.3% | 22+4337%95.2% | 0.5+551%37.1% | 0.1—58.4% | — | |
| Research and development | 0.3−52.4%2.5% | 0.7−44.7%3.9% | 1.2−31.1%4.0% | 1.7−58.0%9.4% | 4.1+70.7%19.9% | 2.4+10.3%10.4% | 2.2—9.6% | — | — | — | |
| Selling and marketing | 2.9−52.1%23.1% | 6.0−30.5%36.0% | 8.6+15.2%29.2% | 7.5+27.5%40.7% | 5.9+20.8%28.5% | 4.9−30.3%21.0% | 7.0+331%30.7% | 1.6+31.9%123% | 1.2+135%955% | 0.5—613% | |
| General and administrative | 8.2−23.5%65.7% | 11−28.2%64.2% | 15+13.1%50.3% | 13−2.0%71.6% | 13−1.8%65.2% | 14−19.6%59.0% | 17+120%74.8% | 7.7+68.5%588% | 4.6+81.4%3573% | 2.5—2973% | |
| Operating expenses | 11−34.5%91.3% | 17−29.8%104% | 25+10.4%83.5% | 22−4.4%122% | 23+11.8%114% | 21−19.9%90.4% | 26+144%115% | 11+49.5%816% | 7.2r7.2+86.4%5586% | 3.9—4526% | |
| Operating income | 0.2—1.9% | −1.9−154%−11.4% | 3.5—12.0% | −6.6—−35.8% | −6.1—−29.7% | −0.0—−0.1% | −4.5—−19.8% | −10—−779% | −7.1—−5528% | −3.8—−4426% | |
| Interest expense and finance costs | 7.1+29.9%57.3% | 5.5−25.6%33.0% | 7.4+47.3%24.9% | 5.0+61.7%27.3% | 3.1−48.2%15.0% | 6.0−78.3%25.9% | 28—121% | — | — | — | |
| Share of profit of associates | — | — | −1.7—−5.8% | −1.9—−10.4% | −2.7—−13.3% | −2.1r−2.3—−8.9% | −0.4—−1.8% | — | — | — | |
| Other non-operating income (expense) | — | — | — | — | — | — | — | −0.1—−6.6% | −0.0—−5.1% | −2.2—−2552% | |
| Income before tax | −7.5—−60.1% | −6.4—−38.6% | −3.8—−12.8% | −11—−57.4% | −16−1736%−77.2% | 1.0r0.7—4.2% | −55—−240% | −10—−785% | −7.1—−5533% | −5.9—−6979% | |
| Income tax | 0.0−69.0%0.1% | 0.0—0.2% | −0.1−198%−0.2% | 0.1+140%0.3% | 0.0—0.1% | −0.4−332%−1.6% | 0.2+8532%0.7% | 0.0−26.9%0.1% | 0.0+30.0%2.0% | 0.0—2.4% | |
| Net income including minority interests | −7.5—−60.2% | −6.5—−38.7% | −3.7—−12.6% | −11—−57.8% | −16−1278%−77.4% | 1.4r1.1—5.8% | −55—−241% | −10—−785% | −7.1—−5535% | — | |
| Minority interests' share of net income | — | — | — | — | — | — | — | 0.7—55.8% | 0—0.0% | — | |
| Net income attributable to shareholders | −7.5—−60.2% | −6.5—−38.7% | −3.7—−12.6% | −11—−57.8% | −16−1278%−77.4% | 1.4r1.1—5.8% | −55—−241% | −9.6—−730% | −7.1—−5535% | −5.9—−6981% | |
| Earnings per share, basic | -0.12—— | -0.10—— | -0.07—— | -0.21—— | -0.32r-320.00−101%— | 30.00r0.02—— | -1.30—— | -1.86—— | -2.52—— | -9.26—— | |
| Earnings per share, diluted | -0.12—— | -0.10—— | -0.07—— | -0.21—— | -0.32r-320.00−101%— | 30.00r0.02—— | -1.30—— | -1.86—— | -2.52—— | -9.26—— | |
| Shares, weighted average (basic) | 64+1.3%— | 63+19.1%— | 53+7.4%— | 49+0.4%— | 49+0.7%— | 49+15.7%— | 42—— | — | — | — | |
| Shares, weighted average (diluted) | 64+1.3%— | 63+19.1%— | 53+7.4%— | 49+0.4%— | 49—— | — | — | 5.2+84.6%— | 2.8+339%— | 0.6—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 2.1+53.1%9.9% | 1.4−45.5%5.9% | 2.5+26.0%7.2% | 2.0−11.3%4.2% | 2.3−8.4%4.0% | 2.5+40.6%4.2% | 1.8−45.6%3.0% | 3.3−40.3%63.2% | 5.4+1612%89.4% | 0.3—62.1% | |
| Short-term investments | — | — | — | — | — | — | 28—47.0% | — | — | — | |
| Receivables | 2.8+6.9%13.1% | 2.6−52.5%11.1% | 5.5r5.5+1373%15.7% | 0.4−63.9%0.8% | 1.0+425%1.8% | 0.2−90.8%0.3% | 2.2+3297%3.6% | 0.1+874%1.2% | 0.0+27.5%0.1% | 0.0—1.0% | |
| Inventory | 1.6−4.9%7.3% | 1.6−4.4%6.9% | 1.7−28.1%4.9% | 2.4−45.8%4.9% | 4.4−38.0%7.7% | 7.1−11.1%11.9% | 8.0—13.4% | — | — | — | |
| Other current assets | 0.4+58.8%1.7% | 0.2−62.1%1.0% | 0.6+32.7%1.7% | 0.4+14.0%0.9% | 0.4−38.7%0.7% | 0.6r1.1−3.6%1.1% | 0.7+395%1.1% | 0.1+512%2.6% | 0.0+17.0%0.4% | 0.0—3.7% | |
| Current assets | 7.7+14.5%36.1% | 6.8−41.2%28.7% | 12+83.0%32.7% | 6.3−30.8%13.0% | 9.1−19.2%16.0% | 11−72.7%18.9% | 41+1074%69.3% | 3.5−38.3%68.1% | 5.7+1317%93.4% | 0.4r1.2—78.5% | |
| Property, plant and equipment | 0.1+146%0.5% | 0.0−22.0%0.2% | 0.1−21.3%0.2% | 0.1−49.0%0.2% | 0.1+22.5%0.3% | 0.1−20.5%0.2% | 0.2+36.3%0.3% | 0.1−8.2%2.2% | 0.1+1171%2.0% | 0.0—1.9% | |
| Right-of-use (leased) assets | 0.8−49.9%3.6% | 1.5−34.5%6.5% | 2.3−16.5%6.6% | 2.8−19.7%5.8% | 3.5−14.4%6.1% | 4.1−9.0%6.8% | 4.5—7.5% | — | — | — | |
| Goodwill | — | — | — | — | — | — | — | 1.4—26.9% | — | — | |
| Other intangible assets | — | — | — | — | — | — | — | 0.1+93.5%2.3% | 0.1−30.9%1.0% | 0.1—17.0% | |
| Investments in associates | — | — | — | 19+6.9%39.0% | 18+10.6%31.1% | 16+19.5%26.7% | 13—22.4% | — | — | — | |
| Long-term investments | — | — | — | — | — | — | — | — | 0.2—3.2% | — | |
| Total assets | 21−9.2%100% | 24−32.9%100% | 35−27.1%100% | 48−15.0%100% | 57−4.7%100% | 60r59+0.1%100% | 59+1054%100% | 5.2−15.5%100% | 6.1+1090%100% | 0.5r1.3—100% | |
| Accounts payable | 6.0+15.5%27.9% | 5.2+1.2%21.9% | 5.1r5.9+35.1%14.5% | 3.8+39.2%7.8% | 2.7r2.6+34.4%4.8% | 2.0−72.2%3.4% | 7.3+1998%12.2% | 0.3−52.9%6.7% | 0.7+72.7%12.1% | 0.4—83.3% | |
| Current liabilities | 69+8.7%322% | 64+3.3%269% | 62+13.2%175% | 54+46.4%113% | 37+58.7%65.4% | 23−28.8%39.3% | 33+2717%55.2% | 1.2−24.6%22.6% | 1.5+0.3%25.3% | 1.5—301% | |
| Long-term debt | — | — | — | — | — | — | — | 0.6—11.4% | — | — | |
| Lease liabilities (non-current) | 1.4+72.9%6.6% | 0.8−55.7%3.5% | 1.8−28.0%5.2% | 2.6−21.7%5.3% | 3.3−6.0%5.7% | 3.5−11.7%5.8% | 3.9—6.6% | — | — | — | |
| Non-current liabilities | — | — | — | — | — | — | 38+5284%63.4% | 0.7+20485%13.6% | 0.0−90.6%0.1% | 0.0—7.0% | |
| Total liabilities | 85+6.2%397% | 80−3.4%339% | 83+0.8%236% | 82+5.3%171% | 78+20.9%138% | 65−8.2%109% | 71+3680%119% | 1.9+20.4%36.2% | 1.5−1.8%25.4% | 1.6—308% | |
| Retained earnings | −270—−1260% | −263—−1113% | −256—−728% | −252—−523% | −241—−425% | −225r−225—−378% | −226—−380% | −85—−1655% | −76—−1241% | −69—−13383% | |
| Shareholders' equity | −64—−297% | −56—−239% | −48—−136% | −34—−70.7% | −21—−37.8% | −5.2r−5.4—−8.7% | −11−375%−18.6% | 4.0−11.6%78.0% | 4.5—74.6% | −1.1r−0.3—−208% | |
| Minority interests | — | — | — | — | — | — | — | −0.7—−14.3% | — | — | |
| Total equity | — | — | — | — | — | — | — | −12r3.3−354%−224% | 4.5—74.6% | — | |
| Total liabilities and equity | 21−9.2%100% | 24−32.9%100% | 35−27.1%100% | 48−15.0%100% | 57−4.7%100% | 60r59+0.1%100% | 59+1054%100% | 5.2−15.5%100% | 6.1+1090%100% | 0.5r1.3—100% | |
| Shares outstanding | 70+9.9%— | 64+3.3%— | 62+24.7%— | 50+0.6%— | 49+0.7%— | 49r49+1.1%— | 48+554%— | 7.4+72.3%— | 4.3+121%— | 1.9—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.0+77.3%0.3% | 0.0−31.3%0.1% | 0.0−39.6%0.1% | 0.1−10.2%0.3% | 0.1−1.7%0.3% | 0.1−17.8%0.3% | 0.1−38.1%0.3% | 0.1+142%9.0% | 0.0+576%37.9% | 0.0—8.5% | |
| Share-based compensation | 0.0−90.2%0.2% | 0.3−79.7%1.5% | 1.3+7788%4.3% | 0.0−97.1%0.1% | 0.6−25.2%2.7% | 0.7—3.2% | — | 1.6−23.9%121% | 2.1+150%1623% | 0.8r0.8—981% | |
| Cash from operating activities | −0.0—−0.1% | −2.3—−13.7% | −1.5—−5.1% | −5.1—−27.6% | −1.3—−6.1% | −2.5—−10.6% | −4.5—−19.9% | −9.0—−687% | −4.8—−3729% | −3.0—−3500% | |
| Capital expenditure | −0.0—−0.0% | −0.0—−0.1% | −0.0—−0.1% | −0.0—−0.1% | −0.1—−0.4% | −0.0—−0.1% | −0.1—−0.3% | −0.1—−4.2% | −0.1—−99.5% | −0.0—−4.7% | |
| Intangible assets bought | — | — | — | — | — | — | — | — | −0.0—−1.6% | −0.1—−92.0% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | −0.3—−23.3% | — | — | |
| Cash from investing activities | 2.2−13.2%17.4% | 2.5—15.0% | −0.4—−1.5% | −2.4—−13.0% | −6.4−217%−30.9% | 5.5—23.6% | −1.5—−6.5% | −0.4—−27.5% | −0.5—−373% | −0.1—−96.7% | |
| Debt repaid | — | — | — | — | — | — | — | −0.0—−2.8% | — | — | |
| Shares issued | — | — | — | — | — | 0.1−98.3%0.6% | 8.6+823%37.8% | 0.9−68.8%70.7% | 3.0—2320% | — | |
| Cash from financing activities | −1.4—−11.4% | −1.4−155%−8.1% | 2.5−65.8%8.4% | 7.2−2.4%39.3% | 7.4—36.0% | −2.3−159%−10.0% | 3.9−46.1%17.1% | 7.2−30.7%548% | 10+253%8095% | 2.9—3463% | |
| Change in cash | 0.7—5.9% | −1.2−320%−7.0% | 0.5—1.8% | −0.3—−1.4% | −0.2−129%−1.0% | 0.7—3.1% | −2.1—−9.4% | −2.2−143%−167% | 5.1—3993% | −0.1—−134% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 16+11.0%100% | 6.3+124%100% | 2.0−17.6%100% | 3.9*+17.0%100% | 3.4−38.3%100% | 2.8−47.6%100% | 2.4−4.0%100% | 3.3*−53.4%100% | 5.5+9.2%100% | 5.4—100% | 2.5—100% | 7.1*—100% | 5.0—100% | |
| Cost of revenue | 1.0−7.8%6.4% | 0.3+129%5.4% | 0.2−25.3%8.5% | 0.2*−23.9%6.1% | 0.2−37.3%7.3% | 0.2−37.8%5.3% | 0.2−12.5%9.4% | 0.3*+61.8%9.4% | 0.4+84.1%7.2% | 0.2—4.5% | 0.3—10.3% | 0.2*—2.7% | 0.2—4.3% | |
| Gross profit | 15+12.6%93.6% | 6.0+124%94.6% | 1.8−16.8%91.5% | 3.6*+21.3%93.9% | 3.1−38.4%92.7% | 2.7−48.1%94.7% | 2.2−3.0%90.6% | 3.0*−56.6%90.6% | 5.1+5.8%92.8% | 5.1—95.5% | 2.2—89.7% | 6.9*—97.3% | 4.8—95.7% | |
| Research and development | 0.2−54.0%1.5% | 0.1+107%1.8% | 0.0−77.3%2.0% | 0.0*−77.4%0.8% | 0.1−65.8%1.5% | 0.1−70.7%2.0% | 0.2−3.8%7.3% | 0.1*−17.5%4.2% | 0.1−64.7%2.7% | 0.2—3.6% | 0.2—7.3% | 0.2*—2.3% | 0.4—8.3% | |
| Selling and marketing | 2.8−25.6%18.0% | 0.5−26.9%7.8% | 0.7+15.6%37.7% | 0.9*−19.5%23.3% | 0.7−50.3%19.4% | 0.7−58.7%23.9% | 0.6−66.6%26.8% | 1.1*−51.3%33.9% | 1.3−12.0%24.1% | 1.6—30.3% | 1.9—77.3% | 2.3*—32.4% | 1.5—29.8% | |
| General and administrative | 7.0−28.5%44.8% | 1.6−31.8%24.9% | 1.9−20.9%93.3% | 1.8*−21.2%46.8% | 1.7−38.2%51.2% | 2.3−15.6%81.9% | 2.3−18.5%97.2% | 2.3*−25.4%69.5% | 2.8−2.4%51.1% | 2.7—50.8% | 2.9—114% | 3.1*—43.4% | 2.9—57.2% | |
| Operating expenses | 10.0−28.7%64.3% | 2.2−28.1%34.6% | 2.6−16.6%133% | 2.7*−22.9%70.9% | 2.4−42.9%72.1% | 3.0−33.3%108% | 3.2−36.6%131% | 3.5*−35.9%108% | 4.3−10.8%77.8% | 4.6—84.7% | 5.0—199% | 5.5*—78.1% | 4.8—95.3% | |
| Operating income | 4.5—29.3% | 3.8—60.0% | −0.8—−41.5% | 0.9*—23.0% | 0.7−15.3%20.6% | −0.4−164%−13.1% | −1.0—−40.7% | −0.6*−141%−16.9% | 0.8+3321%15.0% | 0.6—10.8% | −2.7—−109% | 1.4*—19.2% | 0.0—0.5% | |
| Interest expense and finance costs | 7.9+42.7%51.0% | 1.6−4.9%25.3% | 2.1+69.3%107% | 2.3*+77.5%58.9% | 1.9+44.3%57.2% | 1.7+73.7%59.6% | 1.3−34.2%52.2% | 1.3*−41.3%38.8% | 1.3−29.9%24.4% | 1.0—18.0% | 1.9—76.2% | 2.2*—30.8% | 1.9—38.0% | |
| Share of profit of associates | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | −0.4*—−5.2% | −0.4—−7.6% | |
| Income before tax | −5.4—−34.9% | 1.3—21.2% | −3.3—−168% | −1.9*—−50.2% | −1.5−182%−44.3% | −1.7—−61.2% | −2.3—−96.7% | −1.7*−259%−52.9% | 1.8+1639%33.3% | −2.2—−40.0% | −4.4—−174% | 1.1*—15.5% | 0.1—2.1% | |
| Income tax | 0.6—3.9% | −0.0—−0.0% | 0.00.0%0.2% | 0.0*+167%0.4% | 0.6—17.1% | −0.6−2003%−20.9% | 0.0—0.2% | 0.0*—0.2% | −0.0−103%−0.0% | 0.0—0.6% | −0.0—−0.3% | −0.1*—−1.6% | 0.0—0.8% | |
| Net income including minority interests | −6.0—−38.8% | 1.3*—21.2% | −3.3—−168% | −2.0*—−50.6% | −2.1*−214%−61.5% | −1.1*—−40.3% | −2.3—−96.8% | −1.7*−245%−53.1% | 1.8*+2627%33.4% | −2.2*—−40.6% | −4.3—−174% | 1.2*—17.1% | 0.1*—1.3% | |
| Net income attributable to shareholders | −6.0—−38.8% | 1.3—21.2% | −3.3—−168% | −2.0*—−50.6% | −2.1−214%−61.5% | −1.1—−40.3% | −2.3—−96.8% | −1.7*−245%−53.1% | 1.8+2627%33.4% | −2.2—−40.6% | −4.3—−174% | 1.2*—17.1% | 0.1—1.3% | |
| Earnings per share, basic | — | 0.02—— | -0.05—— | — | -0.03−200%— | -0.02—— | -0.04—— | — | 0.03—— | -0.03—— | -0.07—— | — | 0.00—— | |
| Earnings per share, diluted | — | 0.02—— | -0.05—— | — | -0.03−200%— | -0.02—— | -0.04—— | — | 0.03r-0.01—— | -0.03—— | -0.07—— | — | -0.01—— | |
| Shares, weighted average (basic) | 70+9.9%— | 70+9.9%— | 70+9.9%— | — | 640.0%— | 64+0.8%— | 64+3.3%— | — | 64+19.1%— | 63—— | 62—— | — | 54—— | |
| Shares, weighted average (diluted) | 121+88.7%— | 121+88.7%— | 70+9.9%— | — | 640.0%— | 64+0.8%— | 64+3.3%— | — | 64r163−53.8%— | 63—— | 62—— | — | 138—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2.8—17.2% | 2.8+217%17.2% | 1.1−19.6%5.7% | 2.1+53.1%9.9% | 0.3−76.7%1.4% | 0.9−41.9%3.8% | 1.3−22.1%5.9% | 1.4−45.5%5.9% | 1.3−16.6%4.6% | 1.5—5.9% | 1.7—5.8% | 2.5—7.2% | 1.5—3.2% | |
| Receivables | 0.7—4.3% | 0.7−65.8%4.3% | 2.0−0.6%11.0% | 2.8+6.9%13.1% | 2.6−47.0%12.6% | 2.1−55.0%8.9% | 2.1−31.1%9.2% | 2.6−52.5%11.1% | 4.9+7.7%18.1% | 4.6—17.7% | 3.0—10.1% | 5.5r5.5—15.7% | 4.6—9.7% | |
| Inventory | 1.6—9.7% | 1.6+21.0%9.7% | 1.9+32.8%10.2% | 1.6−4.9%7.3% | 1.2−24.7%5.8% | 1.3−19.3%5.6% | 1.4−5.9%6.4% | 1.6−4.4%6.9% | 1.6−2.4%5.9% | 1.6—6.3% | 1.5—5.2% | 1.7—4.9% | 1.7—3.5% | |
| Other current assets | 0.3—1.9% | 0.3+38.6%1.9% | 0.3+46.9%1.7% | 0.4+58.8%1.7% | 0.3−61.4%1.5% | 0.2−66.4%0.9% | 0.2−72.3%0.9% | 0.2−62.1%1.0% | 0.8+26.3%3.0% | 0.7—2.5% | 0.8—2.6% | 0.6—1.7% | 0.6—1.4% | |
| Current assets | 6.0—36.7% | 6.0+19.7%36.7% | 6.0+6.0%32.1% | 7.7+14.5%36.1% | 4.8−48.0%23.1% | 5.0−44.4%21.5% | 5.7−27.9%25.1% | 6.8−41.2%28.7% | 9.2−0.6%33.7% | 9.0—34.7% | 7.8—26.6% | 12—32.7% | 9.3—19.5% | |
| Property, plant and equipment | 0.1—0.5% | 0.1−39.9%0.5% | 0.1+139%0.5% | 0.1+146%0.5% | 0.1+161%0.6% | 0.1+165%0.6% | 0.0−28.1%0.2% | 0.0−22.0%0.2% | 0.0−18.3%0.2% | 0.1—0.2% | 0.1—0.2% | 0.1—0.2% | 0.1—0.1% | |
| Right-of-use (leased) assets | 0.8—4.9% | 0.8−2.7%4.9% | 0.7−44.7%3.9% | 0.8−49.9%3.6% | 0.8−53.5%3.8% | 0.8−56.4%3.6% | 1.3−36.1%5.9% | 1.5−34.5%6.5% | 1.7−31.5%6.3% | 1.9—7.3% | 2.1—7.0% | 2.3—6.6% | 2.5—5.3% | |
| Investments in associates | — | — | — | — | — | — | — | — | — | — | — | — | 18—37.4% | |
| Total assets | 16—100% | 16−29.9%100% | 19−16.8%100% | 21−9.2%100% | 21−24.1%100% | 23−10.0%100% | 22−23.9%100% | 24−32.9%100% | 27−42.4%100% | 26—100% | 30—100% | 35—100% | 47—100% | |
| Accounts payable | 4.3—26.6% | 4.3−4.7%26.6% | 5.8+20.9%31.1% | 6.0+15.5%27.9% | 5.4−17.4%25.8% | 4.6−36.8%19.5% | 4.8−26.8%21.4% | 5.2+1.2%21.9% | 6.5+35.0%23.7% | 7.2—27.8% | 6.6—22.2% | 5.1r5.9—14.5% | 4.8—10.1% | |
| Current liabilities | 66—404% | 66+6.5%404% | 71+8.7%377% | 69+8.7%322% | 64+0.1%309% | 62−3.0%266% | 65+4.0%289% | 64+3.3%269% | 64+5.3%235% | 64—247% | 62—211% | 62—175% | 61—128% | |
| Lease liabilities (non-current) | 1.3—7.9% | 1.3−18.0%7.9% | 1.3+143%7.1% | 1.4+72.9%6.6% | 1.5+39.2%7.2% | 1.6+19.8%6.8% | 0.5−65.2%2.4% | 0.8−55.7%3.5% | 1.1−48.0%3.9% | 1.3—5.1% | 1.6—5.3% | 1.8—5.2% | 2.1—4.4% | |
| Total liabilities | 83—504% | 83+4.4%504% | 87+6.8%463% | 85+6.2%397% | 80−1.1%387% | 79−4.7%339% | 81−2.5%361% | 80−3.4%339% | 81−3.2%297% | 83—320% | 83—282% | 83—236% | 84—177% | |
| Retained earnings | −272—−1662% | −272—−1662% | −273—−1462% | −270—−1260% | −268—−1292% | −266—−1140% | −265—−1179% | −263—−1113% | −261—−954% | −263—−1013% | −260—−882% | −256—−728% | −257—−542% | |
| Shareholders' equity | −66—−404% | −66—−404% | −68—−363% | −64—−297% | −59—−287% | −56—−239% | −59—−261% | −56—−239% | −54—−197% | −57—−220% | −54—−182% | −48—−136% | −36—−76.6% | |
| Total liabilities and equity | 16—100% | 16−29.9%100% | 19−16.8%100% | 21−9.2%100% | 21−24.1%100% | 23−10.0%100% | 22−23.9%100% | 24−32.9%100% | 27−42.4%100% | 26—100% | 30—100% | 35—100% | 47—100% | |
| Shares outstanding | 70—— | 70+9.9%— | 70+9.9%— | 70+9.9%— | 640.0%— | 640.0%— | 64+3.3%— | 64+3.3%— | 64+19.1%— | 64—— | 62—— | 62—— | 54—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1+211%0.4% | 0.0*+250%0.2% | 0.0+200%0.8% | 0.0*+200%0.4% | 0.0*+200%0.4% | 0.0*−33.3%0.1% | 0.0−16.7%0.2% | 0.0*−16.7%0.2% | 0.0*−37.5%0.1% | 0.0*—0.1% | 0.0—0.2% | 0.0*—0.1% | 0.0*—0.2% | |
| Share-based compensation | 0.0—0.1% | 0*—0.0% | 0.0−90.0%0.1% | 0.0*−75.9%0.2% | 0.0*−67.9%0.3% | — | 0.0−94.1%0.4% | 0.0*+26.1%0.9% | 0.0*+16.7%0.5% | 0.0*—0.5% | 0.2—6.8% | 0.0*—0.3% | 0.0*—0.5% | |
| Cash from operating activities | 4.0—25.5% | 1.7*—26.8% | −0.3−223%−17.4% | 2.2*+544%57.3% | 0.4*+176%12.1% | −2.9*—−103% | 0.3+99.3%11.6% | 0.3*−66.9%10.4% | 0.1*+155%2.7% | −2.9*—−54.2% | 0.1—5.6% | 1.0*—14.7% | 0.1*—1.2% | |
| Capital expenditure | — | — | — | 0*—0.0% | 0*—0.0% | — | — | −0.0*—−0.2% | — | −0.0*—−0.1% | −0.0—−0.2% | −0.0*—−0.1% | 0*—0.0% | |
| Cash from investing activities | 1.6−27.3%10.2% | 1.6*−27.3%25.0% | 0—0.0% | 0*—0.0% | 0*−100%0.0% | 2.2*−13.3%77.1% | 0—0.0% | −0.0*—−0.1% | 0.0*—0.0% | 2.5*—46.6% | −0.0—−0.2% | −0.0*—−0.1% | −0.4*—−8.0% | |
| Cash from financing activities | −3.6—−23.2% | −1.5*−640%−24.3% | −0.7—−35.4% | −0.4*—−9.4% | −1.0*—−29.7% | 0.3*+20.9%10.1% | −0.3—−14.3% | −0.2*—−5.9% | −0.4*−189%−8.0% | 0.2*—4.4% | −1.0—−38.1% | −0.0*—−0.1% | 0.5*—9.8% | |
| Change in cash | 1.9—12.4% | 1.7*—27.5% | −1.1—−53.2% | 1.8*+1269%47.6% | −0.6*—−17.5% | −0.4*—−15.9% | −0.1—−2.3% | 0.1*−87.1%4.1% | −0.3*−288%−4.9% | −0.2*—−3.5% | −0.8—−33.3% | 1.0*—14.7% | 0.1*—2.9% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Emmaus Life Sciences, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Endari - US$9 M73%-33%
- Endari - International$3 M26%+19%
- Other$0 M1.8%-57%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where Emmaus Life Sciences, Inc. operates: 5 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 7 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office2 subsidiaries | — |
| 🇰🇷 South Korea | 2 subsidiaries | — |
| 🇮🇪 Ireland | 1 subsidiary | — |
| 🇯🇵 Japan | 1 subsidiary | — |
| 🇬🇧 UK | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Events at Emmaus Life Sciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Auditor changed 3 · Directors and officers 9 · Material agreement 5 · New debt 2 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K | |
| Directors and officers | 8-K | |
| Auditor changedResults announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 14, 2026
Acquisitions and funding#
4 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2020 | $4 M | Private placement after listing | $2 to $10 million | 18 | options | SEC |
| Jan 2011 | $3 M | No. 4 | $2 to $10 million | 12 | options | SEC |
| Oct 2010 | $2 M | No. 3 | Under $2 million | 4 | equity, debt, options | SEC |
| Aug 2009 | $2 M | No. 2 | $2 to $10 million | 6 | equity, options | SEC |
| Jun 2009 | $1 M | No. 1 | Under $2 million | 1 | options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Emmaus Life Sciences, Inc. compares in Biotechnology
- Revenue$12 M · higher than 46% of 647
- Net margin-38.8% · higher than 54% of 408
- Revenue growth-25.2% · higher than 28% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Emmaus Life Sciences, Inc.🇺🇸 | $12 M | — | -38.8% | -25.2% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Emmaus Life Sciences, Inc.? Verify and update this profile — free
Show Emmaus Life Sciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.